Top Markets
#1 AntFun AntFun +96.36%
#2 Mubarak Mubarak +49.23%
#3 CZ'S Dog CZ'S Dog +34.34%
#4 SODAX SODAX +26.00%
#5 Bitcoin Cash Bitcoin Cash +21.56%
#6 Mina Protocol Mina Protocol +21.52%
#7 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +21.20%
#8 EXOD EXOD +21.04%
#9 MarsCoin MarsCoin +19.28%
#10 Nillion Nillion +19.23%
Coin of the day
AntFun AntFun
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
शेयरों में रैंक #27
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
शेयर मूल्य
$265.95
मार्केट कैप
$469.88B
बदलाव (1 दिन)
0.34%
बदलाव (1 वर्ष)
19.48%
देश
US
व्यापार AbbVie Inc. (ABBV)

श्रेणी

Healthcare
AbbVie Inc. (ABBV) के लिए P/B अनुपात
September 2026 को P/B अनुपात TTM: -78.09
AbbVie Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/B अनुपात (TTM) -78.09 है। 2024 के अंत में, कंपनी का P/B अनुपात 94.54 था।
AbbVie Inc. के लिए 2009 से 2026 तक P/B अनुपात का इतिहास
हर वर्ष के अंत में P/B अनुपात
वर्ष P/B अनुपात परिवर्तन
2026 (TTM) -78.09 -100.00%
2025 0.00 -100.00%
2024 94.54 257.48%
2023 26.45 59.43%
2022 16.59 6.65%
2021 15.55 13.87%
2020 13.66 -185.13%
2019 -16.05 -4.60%
2018 -16.82 -155.55%
2017 30.28 38.22%
2016 21.91 -10.22%
2015 24.40 -59.27%
2014 59.92 220.74%
2013 18.68 16.62%
2012 16.02 237.93%
2011 4.74 31.60%
2010 3.60 0.00%
2009 0.00 0.00%
समान कंपनियों या प्रतिस्पर्धियों के लिए P/B अनुपात
कंपनी P/B अनुपात P/B अनुपात में अंतर देश
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 29.9692 -138.38%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 7.6479 -109.79%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 8.4776 -110.86%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 8.5385 -110.93%
US
Novartis AG Novartis AG
Novartis AG
NOVN.SW
 6.754 -108.65%
CH